Navigation

Pfizer breast cancer drug fails late-stage test

Pfizer breast cancer drug fails late-stage test
Pfizer says its cancer drug Ibrance did not meet the main goal in a late-stage trial in patients with a type of breast cancer.

Share

Post A Comment:

0 comments:

Leave a comment. Thanks!